CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

Abstract

AIM:

Four Phase II trials (clinical trials numbers: NCT02345863, NCT02401503, NCT02445131 and NCT02689141) evaluate a different combination of targeted agents in an all-comer population of approximately 60 patients with chronic lymphocytic leukemia irrespective of prior treatment, physical fitness and genetic risk factors. Patients with a higher tumor load start with a debulking treatment with bendamustine. The subsequent induction and maintenance treatment with an anti-CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib or venetoclax) are continued until achievement of a complete response and minimal residual disease negativity.

CONCLUSION:

This strategy represents a new era of chronic lymphocytic leukemia therapy where chemotherapy is increasingly replaced by targeted agents and treatment duration is tailored to the patient's individual tumor load and response.

• Authors: Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Anja Engelke, Petra Langerbeins, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
• Journal: Future oncology (London, England) (Future Oncol) Vol. 14 Issue 6 Pg. 499-513 (Mar 2018) ISSN: 1744-8301 [Electronic] England
• PMID: 29465308 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Bridged Bicyclo Compounds, Heterocyclic
• Purines
• Quinazolinones
• Sulfonamides
• Bendamustine Hydrochloride
• ofatumumab
• venetoclax
• obinutuzumab
• idelalisib

Topics

• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bendamustine Hydrochloride (administration & dosage)
• Bone Marrow (pathology)
• Bridged Bicyclo Compounds, Heterocyclic (administration & dosage)
• Humans
• Induction Chemotherapy
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, pathology)
• Maintenance Chemotherapy
• Molecular Targeted Therapy
• Neoplasm, Residual (drug therapy, pathology)
• Purines (administration & dosage)
• Quinazolinones (administration & dosage)
• Sulfonamides (administration & dosage)
• Treatment Outcome